Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBLTT52CAR19 in Relapsed/Refractory B-ALL
NCT04557436Phase 1Completed
- Sponsor
- Great Ormond Street Hospital
- Start
- Aug 2020
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBLTT52CAR19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Great Ormond Street Hospital. Primary endpoint: B-ALL remission at 28 days. Started Aug 2020; status: completed.
02
Drugs
PBLTT52CAR19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04557436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557436.